We recently reported a b 3 -decapeptide, bWWI-1, that binds a validated gp41 model in vitro and inhibits gp41-mediated fusion in cell culture. Here we report six analogs of bWWI-1 containing a variety of nonnatural side chains in place of the central tryptophan of the WWI-epitope. These analogs were compared on the basis of both gp41 affinity in vitro and fusion inibition in live, HIV-infected cells. -decapeptides (bWXI-af) containing a variety of nonnatural side chains in place of the central tryptophan of the WWI-epitope (Fig. 1) . These nonnatural residues included those with both extended or alternative p-systems (bWXI-b,d) and halogen-substituted aromatic rings (bWXIa,c,e,f) to probe the steric and electronic requirements of the N-peptide surface pocket in the context of a b 3 -peptide. bWWI-1, a previously described b-peptide HIV fusion inhibitor, 25 was synthesized as a positive control. Each b-peptide was labeled at the N-terminus with 6-(fluorescein-5(6)-carboxamido) hexanoic acid N-hydroxy-succinimidyl ester (Flu) and employed in a direct fluorescence polarization (FP) assay to determine its affinity for IQN17, a fusion protein containing 17 residues from the gp41 N-terminus joined to a 29 residue isoleucine zipper.
a b s t r a c t
We recently reported a b 3 -decapeptide, bWWI-1, that binds a validated gp41 model in vitro and inhibits gp41-mediated fusion in cell culture. Here we report six analogs of bWWI-1 containing a variety of nonnatural side chains in place of the central tryptophan of the WWI-epitope. These analogs were compared on the basis of both gp41 affinity in vitro and fusion inibition in live, HIV-infected cells. One new b
3
-peptide, bWXI-a, offers a significantly improved CC 50 /EC 50 ratio in the live cell assay.
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Linear peptides derived from the C-terminus of HIV-1 gp41 (Cpeptides) are potent HIV fusion inhibitors. 1 These molecules bind to the gp41 N-peptide region and inhibit an intramolecular protein-protein interaction that drives fusion of viral and host cell membranes. [2] [3] [4] Previous work has shown that the protein-protein interface consists of a highly conserved pocket on the N-peptide surface that is occupied by three C-peptide side chains: Trp-628, Trp-631 and Ile-635. [3] [4] [5] These three residues comprise the WWI epitope. -decapeptides (bWXI-af) containing a variety of nonnatural side chains in place of the central tryptophan of the WWI-epitope (Fig. 1 ). These nonnatural residues included those with both extended or alternative p-systems (bWXI-b,d) and halogen-substituted aromatic rings (bWXIa,c,e,f) to probe the steric and electronic requirements of the N-peptide surface pocket in the context of a b 3 -peptide. bWWI-1, a previously described b-peptide HIV fusion inhibitor, 25 was synthesized as a positive control. Each b-peptide was labeled at the N-terminus with 6-(fluorescein-5(6)-carboxamido) hexanoic acid N-hydroxy-succinimidyl ester (Flu) and employed in a direct fluorescence polarization (FP) assay to determine its affinity for IQN17, a fusion protein containing 17 residues from the gp41 N-terminus joined to a 29 residue isoleucine zipper.
10 IQN17 exists as a stable trimer in solution if not surprising, given the loss of affinity that typically results from altering the central tryptophan residue. 6, 25 All seven b-peptides were evaluated for the ability to promote cell survival in an MTT colorimetric assay. 26, 27 In this method, Interestingly, two of the most potent new b-peptides (bWXI-c and f) share little structural similarity, with halogen substituents at para-and ortho-positions, respectively. bWXI-a and e, with EC 50 = 18-19 lM, share a fluorine-containing substituent at the meta position of the phenyl side chain.
We also compared the new b-peptides in terms of cytotoxicity, determined as the viability of uninfected cells in the presence of inhibitor alone (Fig. S1 , Table 1 The ability of bWXI-a to bind IQN17 and inhibit fusion in the MTT assay may be partially rationalized by a simple model in which the indole side chain of the central tryptophan is replaced by the central aromatic side chains of our b-peptides (Fig. 3) . A crystal structure of the gp41 fusion peptide solved by Sia et al. 11 depicts the epitope-containing a-peptide C14linkmid bound to IQN17 and clearly shows association between the indole side chain and the N-peptide surface pocket. Substitution of the Trp indole ring of C14linkmid with the m-trifluoromethylphenyl side chain in bWXI-a suggests that the trifluoro-methylbenzene side chain is a reasonable structural mimic of the indole ring, whereas the 3-pyridyl side chain is not. Although bWXI-a is not as potent as Fuzeon in the MTT assay (EC 50 = 37.5 nM), it has a significantly lower mass (1457 Da vs 4492 for Fuzeon), and higher metabolic and proteolytic stablity. [31] [32] [33] [34] [35] Furthermore, due to the ability of the 14-helical scaffold to tolerate changes to the epitope face, it may be possible to identify b 3 -peptides with further improved activity and decreased toxicity through combinatorial optimization. 
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